Auditory-perceptual acuity in rhotic misarticulation: baseline characteristics and treatment response

Background:The frequency of comorbidities has increased in spondyloarthritis patients compared to the general population. The effect of comorbidities on tumour necrosis factor alpha inhibitor (TNFi) drug retention and treatment response has not been well evaluated.Objectives:The purpose of this study to assess the impact of comorbidities on the first TNFi drug survival and treatment response in patients with axial spondyloarthritis (axSpA) registered in theTURKBIOdatabase.Methods:In this study, the frequency of comorbidities, disease activity scores at baseline and month 6 and drug retention were recorded in AxSpA patients iniating first TNFi treatment between 2011 and 2019. Kaplan Meier plot and log rank tests were used for drug survival analysis. Cox regression analysis with HR was performed to evaluate the correlation between comorbidities and drug survival.Results:There were 2428 patients with AxSpA (39.3% female) who used their first TNFi during the study period. Among them, a total of 770 (31%) had at least one comorbid disease. Hypertension was the most common comorbidity (9.7%), followed by the affective disorders (8%) and chronic lung disease (5.8%). The baseline characteristics of patients are shown in Table 1.The presence of any comorbidity did not impact the first TNFi retention (Figure 1). When comorbidities were analysed seperately, we found that only history of cerebrovascular event was negatively associated with drug retention rate (HR: 6.9, p:0.008). There was no statistically significant difference in Bath AS Disease Activity Index 50% (BASDAI50) response between patients with and without comorbidity at 6 months. Less axSpA patients with comorbidity achieved a ASDAS score ≤ 2.1 compared to patients without comorbidity at 6 months.Table 1.Baseline Characteristics of PatientsRadiographic Spondyloarthritis, n (%)2318 (95.5)Female, n(%)954 (39.3)Age, year42.2±11.8Age at diagnosis, years32.5± 11.3Age at initial TNFi, years39.4 ± 11.1Symptom duration, years9.7± 7.5Time to initial TNFi, years7±6.8HLA-B27- positivity, n (%)1144 (47.1)Smokers, n (%)1068 (44)Baseline BASDAI35.5±22.2Baseline ASDAS-CRP2.8±1.1Baseline CRP (mg/L)15.7±24.4VAS global patient46.6±28.7-Quantitative variables are presented as mean ± SD, and qualitative variables are presented as frequency and percentage-ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score using C-reactive protein VAS, visual analogue scaleConclusion:The results of this study demonstrated that the presence of previous cerebrovascular event decreased the first TNFi survival in patients with axSpA. It also suggested that comorbidities might decrease TNFi treatment response.Disclosure of Interests:None declared

Download Full-text

OR10-3 BASELINE CHARACTERISTICS AND TREATMENT RESPONSE TO GH IN GH-DEFICIENT CHILDREN REPORTED TO THE NordiNet® OUTCOME DATABASE

Growth Hormone & IGF Research ◽

10.1016/s1096-6374(07)70243-5 ◽

2006 ◽

Vol 16 ◽

pp. S20

Author(s):

Viatcheslav Rakov ◽

Lars Savendahl ◽

Jenny Faerch

Keyword(s):

Treatment Response ◽

Baseline Characteristics

Download Full-text

An evaluation of factors influencing response to epicutaneous immunotherapy for peanut allergy in the PEPITES trial

Allergy and Asthma Proceedings ◽

10.2500/aap.2020.41.200047 ◽

2020 ◽

Vol 41 (5) ◽

pp. 326-335 ◽

Cited By ~ 1

Author(s):

David M. Fleischer ◽

Sharon Chinthrajah ◽

Amy M. Scurlock ◽

Dianne E. Campbell ◽

Todd D. Green ◽

...

Keyword(s):

Treatment Response ◽

Peanut Allergy ◽

Geometric Mean ◽

Specific Ige ◽

Double Blind ◽

Treatment Benefit ◽

Patch Application ◽

Epicutaneous Immunotherapy ◽

Lower Baseline ◽

Baseline Characteristics

Background: Epicutaneous immunotherapy (EPIT) for peanut allergy is a potential novel immunotherapy that utilizes the unique cutaneous immunologic properties to induce desensitization. A randomized, double-blind, placebo-controlled Phase 3 trial (PEPITES) in peanut-allergic children 4‐11 years demonstrated an epicutaneous patch (DBV712) with 250 µg peanut protein was statistically superior to placebo in inducing desensitization following 12 months of daily treatment. Objective: To investigate what baseline and in-study factors influenced response to DBV712 250 µg, with a focus on patch adhesion, by posthoc analysis of PEPITES data. Methods: A posthoc multivariate model built with log-transformed Month 12 eliciting dose (ED) as the dependent variable was used to assess the influence of baseline characteristics and patch adhesion. Baseline characteristics and treatment response were also evaluated by stratifying subjects into decile subgroups by patch detachment rates over the 12-month study. Results: Multivariate analysis identified higher baseline ED and lower baseline peanut-specific IgE as the variables most predictive of higher Month 12 ED, followed by mean daily patch application duration, baseline SCORing Atopic Dermatitis (SCORAD) score, and age. By decile stratification, no association between patch detachment and treatment response was identified for 80% of DBV712-treated subjects. All DBV712-treated subjects, including those with the highest patch detachment rates, demonstrated treatment benefit measured by fold-changes in geometric mean ED. Conclusion: We identified subject baseline characteristics of higher baseline ED and lower baseline peanut-specific IgE as most predictive of higher Month 12 ED. For the majority of treated subjects, patch detachment did not impact treatment response. A minority of subjects, highly sensitive to peanut at baseline, had lower prespecified responder rates and higher patch detachment rates, yet still benefited from treatment based upon fold-changes in ED.

Download Full-text

Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD

Journal of Ophthalmology ◽

10.1155/2016/4367631 ◽

2016 ◽

Vol 2016 ◽

pp. 1-13 ◽

Cited By ~ 11

Author(s):

Miltiadis K. Tsilimbaris ◽

Maria I. López-Gálvez ◽

Roberto Gallego-Pinazo ◽

Philippe Margaron ◽

George N. Lambrou

Keyword(s):

Treatment Outcomes ◽

Treatment Response ◽

Disease Duration ◽

Case Reports ◽

Predictive Biomarkers ◽

Age Related Macular Degeneration ◽

Anti Vegf ◽

Age Related ◽

Pubmed Database ◽

Baseline Characteristics

Purpose. To review the current literature investigating patient response to antivascular endothelial growth factor-A (VEGF) therapy in the treatment of neovascular age-related macular degeneration (nAMD) and to identify baseline characteristics that might predict response.Method. A literature search of the PubMed database was performed, using the keywords: AMD, anti-VEGF, biomarker, optical coherence tomography, treatment outcome, and predictor. The search was limited to articles published from 2006 to date. Exclusion criteria included phase 1 trials, case reports, studies focusing on indications other than nAMD, and oncology.Results. A total of 1467 articles were identified, of which 845 were excluded. Of the 622 remaining references, 47 met all the search criteria and were included in this review.Conclusion. Several baseline characteristics correlated with anti-VEGF treatment response, including best-corrected visual acuity, age, lesion size, and retinal thickness. The majority of factors were associated with disease duration, suggesting that longer disease duration before treatment results in worse treatment outcomes. This highlights the need for early treatment for patients with nAMD to gain optimal treatment outcomes. Many of the identified baseline characteristics are interconnected and cannot be evaluated in isolation; therefore multivariate analyses will be required to determine any specific relationship with treatment response.

Download Full-text

Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics

Expert Opinion on Pharmacotherapy ◽

10.1517/14656566.2010.509717 ◽

2010 ◽

Vol 11 (14) ◽

pp. 2275-2280 ◽

Cited By ~ 5

Author(s):

Birol Emir ◽

Thomas Kevin Murphy ◽

Danielle Lauren Petersel ◽

Ed Whalen

Keyword(s):

Treatment Response ◽

Baseline Characteristics

Download Full-text

Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B

Journal of Hepatology ◽

10.1016/j.jhep.2008.12.019 ◽

2009 ◽

Vol 51 (1) ◽

pp. 11-20 ◽

Cited By ~ 151

Author(s):

Stefan Zeuzem ◽

Edward Gane ◽

Yun-Fan Liaw ◽

Seng G. Lim ◽

Adrian DiBisceglie ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Treatment Response ◽

Chronic Hepatitis B ◽

Baseline Characteristics

Download Full-text

A comprehensive systematic review and meta-analysis of pharmacological and dietary supplement interventions in paediatric autism: moderators of treatment response and recommendations for future research

Psychological Medicine ◽

10.1017/s0033291716003457 ◽

2017 ◽

Vol 47 (7) ◽

pp. 1323-1334 ◽

Cited By ~ 4

Author(s):

A. Masi ◽

A. Lampit ◽

M. M. DeMayo ◽

N. Glozier ◽

I. B. Hickie ◽

...

Keyword(s):

Treatment Response ◽

Biological Markers ◽

Meta Analysis ◽

Geographical Location ◽

Autism Spectrum ◽

Qualitative Assessment ◽

Response To Treatment ◽

Future Research ◽

Qualitative Synthesis ◽

Baseline Characteristics

BackgroundAutism spectrum disorders (ASDs) are pervasive and multifactorial neurodevelopmental conditions, characterized by impairments in social communication and interaction, and restricted, repetitive patterns of behaviour, interests or activities. Treatment options to ameliorate symptoms of ASDs are limited. Heterogeneity complicates the quest for personalized medicine in this population. Our aim was to investigate if there are baseline characteristics of patients that moderate response or trial design features that impede the identification of efficacious interventions for ASDs.MethodLiterature searches of EMBASE, MEDLINE and PsycINFO identified 43 studies for qualitative assessment of baseline characterization of participants and 37 studies for quantitative analysis of moderators of treatment response. Criteria included blinded randomized controlled trials (RCTs) in paediatric ASD, with at least 10 participants per arm or 20 overall, of oral treatments, including pharmacological interventions and dietary supplements.ResultsRandom-effects meta-analysis of 1997 participants (81% male) identified three moderators associated with an increase in treatment response: trials located in Europe and the Middle-East; outcome measures designated primary status; and the type of outcome measure. Inconsistent reporting of baseline symptom severity and intellectual functioning prevented analysis of these variables. Qualitative synthesis of baseline characteristics identified at least 31 variables, with only age and gender reported in all trials. Biological markers were included in six RCTs.ConclusionsFew trials reported adequate baseline characteristics to permit detailed analysis of response to treatment. Consideration of geographical location, baseline severity and intellectual function is required to ensure generalizability of results. The use of biological markers and correlates in ASD trials remains in its infancy. There is great need to improve the application of baseline characterization and incorporation of biological markers and correlates to permit selection of participants into homogeneous subgroups and to inform response to treatment in ASD.

Download Full-text